
1. General Information
Cizumab 400 mg Injection contains bevacizumab, a recombinant monoclonal antibody that targets vascular endothelial growth factor (VEGF). It is an anti-angiogenic cancer medicine that helps inhibit the formation of new blood vessels supplying a tumor.
Cizumab 400 mg is supplied as a 400 mg/16 mL solution for intravenous infusion. It is a prescription medicine and requires specialist supervision.
2. Product Information
| Product Detail | Information |
|---|---|
| Brand | Cizumab 400 mg |
| Active Ingredient | Bevacizumab |
| Strength | 400 mg/16 mL |
| Dosage Form | Solution for IV infusion |
| Drug Class | Anti-VEGF monoclonal antibody |
| Therapeutic Category | Oncology / Anticancer |
| Manufacturer/Marketer | Hetero Drugs / Hetero Healthcare |
| Storage | Refrigerate at 2–8°C; do not freeze |
| Administration | Intravenous infusion by healthcare professional |
The 400 mg/16 mL presentation is also listed in official bevacizumab prescribing information.
3. Uses of Cizumab 400 mg Injection
Bevacizumab may be used, depending on the patient's cancer type and treatment protocol, in conditions including:
- Metastatic colorectal cancer
- Certain types of non-squamous non-small-cell lung cancer
- Recurrent glioblastoma in adults
- Metastatic renal cell carcinoma
- Persistent, recurrent, or metastatic cervical cancer
- Certain epithelial ovarian, fallopian-tube, and primary peritoneal cancers
- In combination with atezolizumab for certain unresectable or metastatic hepatocellular cancers
The exact indication and combination therapy depend on the applicable country's approved labeling and the treating oncologist's treatment plan.
4. Benefits of Cizumab 400 mg Injection
The principal therapeutic benefit of bevacizumab is its ability to block VEGF-mediated blood-vessel formation.
Potential treatment benefits include:
- Helps restrict blood supply to certain tumors.
- May slow tumor growth and progression.
- Can be combined with chemotherapy or other anticancer medicines in specific treatment protocols.
- Provides an established anti-angiogenic approach for several cancers.
- May help improve disease-control outcomes in appropriately selected patients.
It should not be described as a universal cancer cure; benefits vary according to cancer type, stage, treatment combination, and individual response.
5. Side Effects of Cizumab 400 mg Injection
Bevacizumab can cause side effects ranging from mild to potentially serious. Important risks include:
- High blood pressure
- Bleeding or hemorrhage
- Protein in the urine
- Delayed wound healing
- Gastrointestinal perforation or fistula
- Blood clots
- Infusion-related reactions
- Kidney-related complications
- Rare neurological complications such as posterior reversible encephalopathy syndrome (PRES)
Some serious adverse effects require immediate medical assessment.
6. Common Side Effects
Commonly reported effects can include:
- Headache
- Weakness or fatigue
- High blood pressure
- Nosebleeds
- Diarrhea
- Nausea
- Reduced appetite
- Muscle or joint pain
- Protein in urine
- Mild bleeding
- Infusion-related reactions
Not every patient experiences these effects, and their severity can differ.
7. How to Use Cizumab 400 mg Injection
Cizumab 400 mg is not a self-administered injection. It is given by a qualified healthcare professional as an intravenous infusion, usually in a hospital, oncology center, or appropriately equipped clinic.
The oncologist determines the dose, treatment interval, duration, and combination with other medicines according to the cancer being treated and the patient's clinical condition. The patient is monitored during treatment for infusion reactions and other complications.
Do not attempt to inject or administer Cizumab without professional supervision.
8. How Cizumab Works
Cizumab contains bevacizumab, which binds to vascular endothelial growth factor (VEGF).
VEGF plays an important role in the formation of new blood vessels. Tumors can use newly formed blood vessels to obtain oxygen and nutrients.
By inhibiting VEGF activity, bevacizumab can reduce tumor-associated blood-vessel formation and thereby help restrict tumor growth and progression.
9. Safety Advice
Important precautions include:
- Use only under the supervision of an oncologist.
- Check blood pressure regularly during treatment.
- Monitoring of urine protein may be required.
- Tell your doctor about any unusual or persistent bleeding.
- Inform your healthcare team before planned surgery.
- Bevacizumab can impair wound healing; official labeling recommends withholding it around major surgery according to specified timing and until adequate wound healing.
- Report severe abdominal pain, significant bleeding, breathing difficulties, chest pain, severe headache, or neurological symptoms immediately.
- Tell your doctor about previous blood-clotting, bleeding, cardiovascular, kidney, or gastrointestinal problems.
- Pregnancy considerations require specialist advice because bevacizumab can cause fetal harm.
- Store the product at 2–8°C and do not freeze.
- Follow the storage and cold-chain requirements applicable to pharmaceutical exports.
10. FAQs
Q1. What is Cizumab 400 mg Injection?
Cizumab 400 mg is an intravenous oncology medicine containing bevacizumab 400 mg/16 mL.
Q2. What is Cizumab 400 mg used for?
It is used in specialist-directed treatment protocols for several cancers, including colorectal, certain lung, kidney, cervical, ovarian/peritoneal cancers and recurrent glioblastoma.
Q3. Is Cizumab 400 mg a chemotherapy medicine?
It is an anti-VEGF monoclonal antibody, rather than a conventional cytotoxic chemotherapy drug. It may nevertheless be administered together with chemotherapy.
Q4. How is Cizumab 400 mg administered?
It is administered by intravenous infusion by trained healthcare professionals.
Q5. Can Cizumab 400 mg be self-injected?
No. It requires professional preparation, administration, and monitoring.
Q6. How should Cizumab 400 mg be stored?
It should generally be refrigerated at 2–8°C and protected from freezing.
Q7. Can Cizumab be used during pregnancy?
Bevacizumab may cause fetal harm, so pregnancy-related use requires careful specialist evaluation.
Q8. Does Cizumab cure cancer?
It is not appropriate to describe it as a universal cure. It is used as part of specific cancer treatment regimens to help control disease.
11. Substitute for Cizumab 400 mg
Possible same-composition alternatives contain bevacizumab 400 mg/16 mL, but the appropriate substitute depends on regulatory approval, availability, clinical requirements, and the oncologist's decision.
One example identified in current product information is Versavo+ 400 Solution for Infusion (bevacizumab 400 mg).
Other bevacizumab brands may also be available in different countries. Substitution should be confirmed by the treating healthcare professional or pharmacist, particularly for oncology biologics.
12. SEO & B2B Keywords
For Phoenix Exim – Nagpur, India, you can use keywords such as:
- Cizumab 400 mg Injection exporter from India
- Cizumab 400 mg supplier from Nagpur India
- Cizumab 400 mg Bevacizumab Injection supplier
- Bevacizumab 400 mg injection exporter India
- Cizumab 400 mg oncology medicine exporter
- Cizumab 400 mg wholesale supplier India
- Cizumab 400 mg pharmaceutical exporter
- Cizumab 400 mg injection international supplier
- Cizumab 400 mg cancer medicine supplier
- Cizumab 400 mg injection export from India
- Bevacizumab 400 mg/16 mL supplier India
- Cizumab 400 mg bulk pharmaceutical supplier
- Cizumab 400 mg injection distributor India
- Cizumab 400 mg oncology medicine supplier
- Cizumab 400 mg injection for international buyers
- Cizumab 400 mg supplier to USA
- Cizumab 400 mg supplier to UK
- Cizumab 400 mg supplier to Australia
- Cizumab 400 mg supplier to Singapore
- Cizumab 400 mg supplier to Canada
- Cizumab 400 mg supplier to South Korea
- Cizumab 400 mg supplier to UAE
- Bevacizumab oncology injection exporter from India
- Anti-cancer injection exporter from Nagpur India
- Pharmaceutical oncology products exporter India
- Cizumab Bevacizumab 400 mg international supplier
- Cizumab 400 mg prescription oncology medicine supplier
- Bevacizumab 400 mg pharmaceutical wholesale exporter
- Cizumab 400 mg cold-chain pharmaceutical supplier
- Phoenix Exim Cizumab 400 mg exporter Nagpur India
Keywords







